Maybe it is just the shock of being post Labor Day and realizing that summer is fading into the rear view mirror or maybe it was something I ate for breakfast that spurred new hope. But I think that this is the year that the patient centric approach to data in life sciences finally takes off. And along with that launch will come the massive rapid migration to cloud and data lake architectures for pharma data.
Really? Why now you may ask?
Yeah – that’s right. Every group I have been talking to is worried that they are sitting atop a jigsaw puzzle of siloed data resources that can’t be assembled fast enough to meet the needs of business and scientific users. Organizations are thinking that they can’t answer their questions about why drugs work in some patients and not others if they can’t link phenotype and genotype data. Groups can’t look across clinical trials. They can’t look beyond and between clinical trials and EMR data. Progressive safety groups are considering using automation and cognitive computing to lower costs in processing events so they can then look in parallel to expanding sensing new signals into 10X current volumes of data within large real world data sets.Continue reading…

A new report by economist Jon Gabel and his colleagues at NORC, a research center affiliated with the University of Chicago, looked at the use of transparency tools in an employer health plan. The analysis found the use of price transparency tools to be spotty. For instance, 75 percent of households either did not log into the transparency tool or did so only one time in the 18-month period of study. Fifteen percent did so twice; but only 1 percent logged in 6 times or more. The authors concluded:
How close to we need to get to cybersecurity crisis in healthcare before we, as an industry take deliberative action?
